Cited 0 times in
유전자재조합 B형 간염바이러스 백신(HG -Ⅱ)의 면역원성 및 안전성
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 남궁란 | - |
dc.contributor.author | 손영모 | - |
dc.date.accessioned | 2020-07-03T17:23:04Z | - |
dc.date.available | 2020-07-03T17:23:04Z | - |
dc.date.issued | 1997 | - |
dc.identifier.issn | 1738-222X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/177494 | - |
dc.description.abstract | Background/Aims . The introduction of Hansenula polymorpha for recombinant hepatitis B vaccine production allowed high product yield with plasmid stability and less glycosylation than conventional Saccharomyces cerevisiae system. A Green Cross HG-II vaccine formulated from HBsAg produced by a recombinant strain of the yeast H. polymorpha was evaluated for immunogenicity and safety in an open label triaL Method ' A 20 ug dose of Green Cross HG-II vaccine was administered intramuscularly at 0, 1 and 6 months at the deltoid region in 118 healthy adults seronegative for HBV markers. The anti-HBs titers were determined at one month after administration of the third dose of vaccine by radioimmunoassay. Results .' The seroconversion rate was 96.8% (90 out of 93), with seroprotective rate of 95.7% (89 out of 93). The geometric mean titers(GMT) of the anti-HBs response was 153.1mIU/ml in seroconverters. An age-dependent effect was observed in the anti-HBs response. But sex-dependent effect was not prominent. Reactogenecity was in incidence and general reactions were short-lasting and a mainly mild in severity. Conclusions .' The results of this study have shown that the Green Cross HG-II vaccine is safe and clinically well tolerated, a nd that it may provide protection against HBV infection. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English, Korean | - |
dc.publisher | Korean Association for the Study of the Liver | - |
dc.relation.isPartOf | Korean Journal of Hepatology (대한간학회지) | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | 유전자재조합 B형 간염바이러스 백신(HG -Ⅱ)의 면역원성 및 안전성 | - |
dc.title.alternative | Immunogenicity and Safety of a 20 ㎍ Dose of the Green Cross Recombinant Hepatitis B Vaccine ( HG -Ⅱ ) in Healthy Adults | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pediatrics (소아청소년과학교실) | - |
dc.contributor.googleauthor | 이계희 | - |
dc.contributor.googleauthor | 이옥재 | - |
dc.contributor.googleauthor | 김영채 | - |
dc.contributor.googleauthor | 남궁란 | - |
dc.contributor.googleauthor | 손영모 | - |
dc.contributor.localId | A01241 | - |
dc.contributor.localId | A01981 | - |
dc.relation.journalcode | J02036 | - |
dc.identifier.eissn | 2093-8047 | - |
dc.contributor.alternativeName | Namgung, Ran | - |
dc.contributor.affiliatedAuthor | 남궁란 | - |
dc.contributor.affiliatedAuthor | 손영모 | - |
dc.citation.volume | 3 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 58 | - |
dc.citation.endPage | 64 | - |
dc.identifier.bibliographicCitation | Korean Journal of Hepatology (대한간학회지), Vol.3(1) : 58-64, 1997 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.